{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T18:44:45Z","timestamp":1787856285604,"version":"build-2784847793"},"reference-count":142,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Natural Science Foundation","award":["82293684"],"award-info":[{"award-number":["82293684"]}]},{"name":"National Natural Science Foundation","award":["82070056"],"award-info":[{"award-number":["82070056"]}]},{"name":"National Natural Science Foundation","award":["82273929"],"award-info":[{"award-number":["82273929"]}]},{"name":"National Natural Science Foundation","award":["2022-I2M-2-002"],"award-info":[{"award-number":["2022-I2M-2-002"]}]},{"name":"National Natural Science Foundation","award":["2021-I2M-1-028"],"award-info":[{"award-number":["2021-I2M-1-028"]}]},{"name":"CAMS Innovation Fund for Medical Sciences","award":["82293684"],"award-info":[{"award-number":["82293684"]}]},{"name":"CAMS Innovation Fund for Medical Sciences","award":["82070056"],"award-info":[{"award-number":["82070056"]}]},{"name":"CAMS Innovation Fund for Medical Sciences","award":["82273929"],"award-info":[{"award-number":["82273929"]}]},{"name":"CAMS Innovation Fund for Medical Sciences","award":["2022-I2M-2-002"],"award-info":[{"award-number":["2022-I2M-2-002"]}]},{"name":"CAMS Innovation Fund for Medical Sciences","award":["2021-I2M-1-028"],"award-info":[{"award-number":["2021-I2M-1-028"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Pulmonary hypertension (PH) is a progressive cardiovascular disease, which may lead to severe cardiopulmonary dysfunction. As one of the main PH disease groups, pulmonary artery hypertension (PAH) is characterized by pulmonary vascular remodeling and right ventricular dysfunction. Increased pulmonary artery resistance consequently causes right heart failure, which is the major reason for morbidity and mortality in this disease. Although various treatment strategies have been available, the poor clinical prognosis of patients with PAH reminds us that further studies of the pathological mechanism of PAH are still needed. Inflammation has been elucidated as relevant to the initiation and progression of PAH, and plays a crucial and functional role in vascular remodeling. Many immune cells and cytokines have been demonstrated to be involved in the pulmonary vascular lesions in PAH patients, with the activation of downstream signaling pathways related to inflammation. Consistently, this influence has been found to correlate with the progression and clinical outcome of PAH, indicating that immunity and inflammation may have significant potential in PAH therapy. Therefore, we reviewed the pathogenesis of inflammation and immunity in PAH development, focusing on the potential targets and clinical application of anti-inflammatory and immunosuppressive therapy.<\/jats:p>","DOI":"10.3390\/ijms25158427","type":"journal-article","created":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T18:04:59Z","timestamp":1722535499000},"page":"8427","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Immunotherapy for Pulmonary Arterial Hypertension: From the Pathogenesis to Clinical Management"],"prefix":"10.3390","volume":"25","author":[{"given":"Yihan","family":"Zhang","sequence":"first","affiliation":[{"name":"State Key Laboratory of Bioactive Substances and Functions of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100050, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Li","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Bioactive Substances and Functions of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100050, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shang","family":"Li","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Bioactive Substances and Functions of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100050, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhou","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Bioactive Substances and Functions of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100050, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiantai","family":"Zhang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Bioactive Substances and Functions of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100050, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2931-5172","authenticated-orcid":false,"given":"Lan","family":"Sun","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Bioactive Substances and Functions of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100050, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,8,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1801913","DOI":"10.1183\/13993003.01913-2018","article-title":"Haemodynamic definitions and updated clinical classification of pulmonary hypertension","volume":"53","author":"Simonneau","year":"2019","journal-title":"Eur. Respir. J."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2200879","DOI":"10.1183\/13993003.00879-2022","article-title":"2022 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"61","author":"Humbert","year":"2023","journal-title":"Eur. Respir. J."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"106099","DOI":"10.1016\/j.rmed.2020.106099","article-title":"Evaluation and management of pulmonary arterial hypertension","volume":"171","author":"Beshay","year":"2020","journal-title":"Respir. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/S2213-2600(15)00543-3","article-title":"A global view of pulmonary hypertension","volume":"4","author":"Hoeper","year":"2016","journal-title":"Lancet Respir. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.37765\/ajmc.2021.88609","article-title":"Pulmonary arterial hypertension: Updates in epidemiology and evaluation of patients","volume":"27","author":"Levine","year":"2021","journal-title":"Am. J. Manag. Care"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/eurheartj\/ehv317","article-title":"2015 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT)","volume":"37","author":"Humbert","year":"2016","journal-title":"Eur. Heart. J."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/nrcardio.2011.87","article-title":"Mechanisms of disease: Pulmonary arterial hypertension","volume":"8","author":"Schermuly","year":"2011","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1801887","DOI":"10.1183\/13993003.01887-2018","article-title":"Pathology and pathobiology of pulmonary hypertension: State of the art and research perspectives","volume":"53","author":"Humbert","year":"2019","journal-title":"Eur. Respir. J."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.2147\/IJGM.S295463","article-title":"Treating Inflammation Associated with Pulmonary Hypertension: An Overview of the Literature","volume":"15","author":"Yoo","year":"2022","journal-title":"Int. J. Gen. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1164\/rccm.201202-0335OC","article-title":"Immune and inflammatory cell involvement in the pathology of idiopathic pulmonary arterial hypertension","volume":"186","author":"Savai","year":"2012","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.hlc.2022.02.007","article-title":"Immune Cells in Pulmonary Arterial Hypertension","volume":"31","author":"Ni","year":"2022","journal-title":"Heart Lung Circ."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Hu, Y., Chi, L., Kuebler, W.M., and Goldenberg, N.M. (2020). Perivascular Inflammation in Pulmonary Arterial Hypertension. Cells, 9.","DOI":"10.3390\/cells9112338"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s12016-011-8265-z","article-title":"The Role of Inflammation and Autoimmunity in the Pathophysiology of Pulmonary Arterial Hypertension","volume":"44","author":"Kherbeck","year":"2013","journal-title":"Clinic. Rev. Allerg. Immunol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1007\/s10067-022-06446-y","article-title":"Pulmonary hypertension in connective tissue diseases: Epidemiology, pathogenesis, and treatment","volume":"42","author":"Cansu","year":"2023","journal-title":"Clin. Rheumatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.rmed.2017.11.020","article-title":"Pulmonary arterial hypertension in the setting of scleroderma is different than in the setting of lupus: A review","volume":"134","author":"Bazan","year":"2018","journal-title":"Respir. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.berh.2016.03.004","article-title":"Connective tissue disease-related pulmonary arterial hypertension","volume":"30","author":"Thakkar","year":"2016","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"210053","DOI":"10.1183\/16000617.0053-2021","article-title":"Pulmonary hypertensionphenotypes in patients with systemic sclerosis","volume":"30","author":"Haque","year":"2021","journal-title":"Eur. Respir. Rev."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"106238","DOI":"10.1016\/j.phrs.2022.106238","article-title":"Immunity and inflammation in pulmonary arterial hypertension: From pathophysiology mechanisms to treatment perspective","volume":"180","author":"Wang","year":"2022","journal-title":"Pharmacol. Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"119151","DOI":"10.1016\/j.lfs.2021.119151","article-title":"Identification of key genes and immune profile in limited cutaneous systemic sclerosis-associated pulmonary arterial hypertension by bioinformatics analysis","volume":"271","author":"Zhang","year":"2021","journal-title":"Life Sci."},{"key":"ref_20","first-page":"1358","article-title":"Single-Cell Analysis Reveals Distinct Immune and Smooth Muscle Cell Populations that Contribute to Chronic Thromboembolic Pulmonary Hypertension","volume":"207","author":"Viswanathan","year":"2023","journal-title":"Am. J. Respir. Cell. Mol. Biol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.rmed.2009.10.004","article-title":"T lymphocyte subset abnormalities in the blood and lung in pulmonary arterial hypertension","volume":"104","author":"Austin","year":"2010","journal-title":"Respir. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1165\/rcmb.2009-0365OC","article-title":"Perivascular T-cell infiltration leads to sustained pulmonary artery remodeling after endothelial cell damage","volume":"45","author":"Cuttica","year":"2011","journal-title":"Am. J. Respir. Cell. Mol. Biol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"L609","DOI":"10.1152\/ajplung.00531.2016","article-title":"Central role of T helper 17 cells in chronic hypoxia-induced pulmonary hypertension","volume":"312","author":"Maston","year":"2017","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3181","DOI":"10.3892\/mmr.2014.3106","article-title":"Regulatory T cells protect against hypoxia-induced pulmonary arterial hypertension in mice","volume":"11","author":"Chu","year":"2015","journal-title":"Mol. Med. Rep."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1016\/j.chest.2016.01.004","article-title":"Regulatory T Cell Dysfunction in Idiopathic, Heritable and Connective Tissue-Associated Pulmonary Arterial Hypertension","volume":"149","author":"Huertas","year":"2016","journal-title":"Chest"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Tian, W., Jiang, S.Y., Jiang, X., Tamosiuniene, R., Kim, D., Guan, T., Arsalane, S., Pasupneti, S., Voelkel, N.F., and Tang, Q. (2021). The Role of Regulatory T Cells in Pulmonary Arterial Hypertension. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.684657"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1161\/CIRCRESAHA.110.236927","article-title":"Regulatory T cells limit vascular endothelial injury and prevent pulmonary hypertension","volume":"109","author":"Tamosiuniene","year":"2011","journal-title":"Circ. Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1183\/09031936.00159911","article-title":"Leptin and regulatory T-lymphocytes in idiopathic pulmonary arterial hypertension","volume":"40","author":"Huertas","year":"2012","journal-title":"Eur. Respir. J."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"247372","DOI":"10.1155\/2014\/247372","article-title":"Effect of Th17 and Treg axis disorder on outcomes of pulmonary arterial hypertension in connective tissue diseases","volume":"2014","author":"Gaowa","year":"2014","journal-title":"Mediat. Inflamm."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1093\/abbs\/gmx095","article-title":"Immune cells and autoantibodies in pulmonary arterial hypertension","volume":"49","author":"Li","year":"2017","journal-title":"Acta Biochim. Et Biophys. Sin."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"L710","DOI":"10.1152\/ajplung.00311.2016","article-title":"The mast cell-B cell axis in lung vascular remodeling and pulmonary hypertension","volume":"312","author":"Breitling","year":"2017","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1136\/thoraxjnl-2020-215460","article-title":"Loss of immune homeostasis in patients with idiopathic pulmonary arterial hypertension","volume":"76","author":"Heukels","year":"2021","journal-title":"Thorax"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1164\/rccm.201403-0442OC","article-title":"Vascular Receptor Autoantibodies in Pulmonary Arterial Hypertension Associated with Systemic Sclerosis","volume":"190","author":"Becker","year":"2014","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1164\/rccm.201302-0403OC","article-title":"Bronchus-associated lymphoid tissue in pulmonary hypertension produces pathologic autoantibodies","volume":"188","author":"Colvin","year":"2013","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1164\/rccm.202009-3481OC","article-title":"Safety and Efficacy of B-Cell Depletion with Rituximab for the Treatment of Systemic Sclerosis-associated Pulmonary Arterial Hypertension: A Multicenter, Double-Blind, Randomized, Placebo-controlled Trial","volume":"204","author":"Zamanian","year":"2021","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Zhang, M.Q., Wang, C.C., Pang, X.B., Shi, J.Z., Li, H.R., Xie, X.M., Wang, Z., Zhang, H.D., Zhou, Y.F., and Chen, J.W. (2023). Role of macrophages in pulmonary arterial hypertension. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1152881"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"6425","DOI":"10.1002\/jcp.26429","article-title":"Macrophage plasticity, polarization, and function in health and disease","volume":"233","author":"Mohammadian","year":"2018","journal-title":"J. Cell. Physiol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"4802","DOI":"10.4049\/jimmunol.1601692","article-title":"A Time- and Compartment-Specific Activation of Lung Macrophages in Hypoxic Pulmonary Hypertension","volume":"198","author":"Pugliese","year":"2017","journal-title":"J. Immunol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1161\/ATVBAHA.120.314639","article-title":"Altered Macrophage Polarization Induces Experimental Pulmonary Hypertension and Is Observed in Patients With Pulmonary Arterial Hypertension","volume":"41","author":"Zawia","year":"2021","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Qiu, H., Zhang, Y., Li, Z., Jiang, P., Guo, S., He, Y., and Guo, Y. (2021). Donepezil Ameliorates Pulmonary Arterial Hypertension by Inhibiting M2-Macrophage Activation. Front. Cardiovasc. Med., 8.","DOI":"10.3389\/fcvm.2021.639541"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1802308","DOI":"10.1183\/13993003.02308-2018","article-title":"CCR2\/CCR5-mediated macrophage-smooth muscle cell crosstalk in pulmonary hypertension","volume":"54","author":"Abid","year":"2019","journal-title":"Eur. Respir. J."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"331","DOI":"10.7150\/ijbs.66472","article-title":"MMP-10 from M1 macrophages promotes pulmonary vascular remodeling and pulmonary arterial hypertension","volume":"18","author":"Chi","year":"2022","journal-title":"Int. J. Biol. Sci."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"3211","DOI":"10.1093\/cvr\/cvac001","article-title":"Targeting RUNX1 as a novel treatment modality for pulmonary arterial hypertension","volume":"118","author":"Jeong","year":"2022","journal-title":"Cardiovasc. Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1164\/rccm.202110-2274OC","article-title":"Macrophage-NLRP3 Activation Promotes Right Ventricle Failure in Pulmonary Arterial Hypertension","volume":"206","author":"Lima","year":"2022","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1086\/675642","article-title":"Histological characterization of mast cell chymase in patients with pulmonary hypertension and chronic obstructive pulmonary disease","volume":"4","author":"Kosanovic","year":"2014","journal-title":"Pulm. Circ."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.21037\/jtd.2018.05.59","article-title":"New dynamic viewing of mast cells in pulmonary arterial hypertension (PAH): Contributors or outsiders to cardiovascular remodeling","volume":"10","author":"Xu","year":"2018","journal-title":"J. Thorac. Dis."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1183\/09031936.00043310","article-title":"Mast cells promote lung vascular remodelling in pulmonary hypertension","volume":"37","author":"Hoffmann","year":"2011","journal-title":"Eur. Respir. J."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"220","DOI":"10.4103\/2045-8932.97609","article-title":"Mast cell number, phenotype, and function in human pulmonary arterial hypertension","volume":"2","author":"Farha","year":"2012","journal-title":"Pulm. Circ."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1164\/rccm.201006-0905OC","article-title":"C-kit-positive cells accumulate in remodeled vessels of idiopathic pulmonary arterial hypertension","volume":"184","author":"Montani","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1086\/677359","article-title":"Imatinib in pulmonary arterial hypertension: C-Kit inhibition","volume":"4","author":"Farha","year":"2014","journal-title":"Pulm. Circ."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Bulfone-Paus, S., and Bahri, R. (2015). Mast Cells as Regulators of T Cell Responses. Front. Immunol., 6.","DOI":"10.3389\/fimmu.2015.00394"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1378\/chest.11-0663","article-title":"Mast cell inhibition improves pulmonary vascular remodeling in pulmonary hypertension","volume":"141","author":"Bartelds","year":"2012","journal-title":"Chest"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Moriyama, H., and Endo, J. (2023). Pathophysiological Involvement of Mast Cells and the Lipid Mediators in Pulmonary Vascular Remodeling. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24076619"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.1038\/s41467-022-30621-z","article-title":"Omega-3 fatty acid epoxides produced by PAF-AH2 in mast cells regulate pulmonary vascular remodeling","volume":"13","author":"Moriyama","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"van Uden, D., Boomars, K., and Kool, M. (2019). Dendritic Cell Subsets and Effector Function in Idiopathic and Connective Tissue Disease-Associated Pulmonary Arterial Hypertension. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.00011"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1183\/09031936.00094706","article-title":"Dendritic cell recruitment in lesions of human and experimental pulmonary hypertension","volume":"29","author":"Perros","year":"2007","journal-title":"Eur. Respir. J."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1378\/chest.14-1678","article-title":"T-helper 17 cell polarization in pulmonary arterial hypertension","volume":"147","author":"Hautefort","year":"2015","journal-title":"Chest"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"van Uden, D., Koudstaal, T., van Hulst, J.A.C., Bergen, I.M., Gootjes, C., Morrell, N.W., van Loo, G., von der Th\u00fcsen, J.H., van den Bosch, T.P.P., and Ghigna, M.R. (2021). Central Role of Dendritic Cells in Pulmonary Arterial Hypertension in Human and Mice. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22041756"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1152\/physrev.00012.2018","article-title":"The Neutrophil\u2019s Role During Health and Disease","volume":"99","author":"Liew","year":"2019","journal-title":"Physiol. Rev."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Effah, C.Y., Drokow, E.K., Agboyibor, C., Ding, L., He, S., Liu, S., Akorli, S.Y., Nuamah, E., Sun, T., and Zhou, X. (2021). Neutrophil-Dependent Immunity During Pulmonary Infections and Inflammations. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.689866"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Taylor, S., Dirir, O., Zamanian, R.T., Rabinovitch, M., and Thompson, A.A.R. (2018). The Role of Neutrophils and Neutrophil Elastase in Pulmonary Arterial Hypertension. Front. Med., 5.","DOI":"10.3389\/fmed.2018.00217"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1016\/j.chest.2021.06.028","article-title":"Severe Pulmonary Arterial Hypertension Is Characterized by Increased Neutrophil Elastase and Relative Elafin Deficiency","volume":"160","author":"Sweatt","year":"2021","journal-title":"Chest"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/nri.2017.105","article-title":"Neutrophil extracellular traps in immunity and disease","volume":"18","author":"Papayannopoulos","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1161\/ATVBAHA.116.307634","article-title":"Neutrophil Extracellular Traps Promote Angiogenesis: Evidence From Vascular Pathology in Pulmonary Hypertension","volume":"36","author":"Aldabbous","year":"2016","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1164\/rccm.202102-0446OC","article-title":"Endogenous Retroviral Elements Generate Pathologic Neutrophils in Pulmonary Arterial Hypertension","volume":"206","author":"Taylor","year":"2022","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"4370","DOI":"10.1016\/j.bmcl.2015.08.049","article-title":"Neutrophil elastase inhibitors for the treatment of (cardio)pulmonary diseases: Into clinical testing with pre-adaptive pharmacophores","volume":"25","author":"Li","year":"2015","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1164\/rccm.201412-2291OC","article-title":"Elafin Reverses Pulmonary Hypertension via Caveolin-1-Dependent Bone Morphogenetic Protein Signaling","volume":"191","author":"Nickel","year":"2015","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/bph.14826","article-title":"The role of chemokines and chemokine receptors in pulmonary arterial hypertension","volume":"178","author":"Mamazhakypov","year":"2021","journal-title":"Br. J. Pharmacol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1465-9921-15-47","article-title":"Inflammatory cytokines in pulmonary hypertension","volume":"15","author":"Groth","year":"2014","journal-title":"Respir. Res."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1161\/CIRCULATIONAHA.109.933762","article-title":"Elevated levels of inflammatory cytokines predict survival in idiopathic and familial pulmonary arterial hypertension","volume":"122","author":"Soon","year":"2010","journal-title":"Circulation"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"4713","DOI":"10.1007\/s10067-021-05773-w","article-title":"Evaluation of serum interleukin-6 (IL-6), IL-13, and IL-17 levels and computed tomography finding in interstitial lung disease associated with connective tissue disease patients","volume":"40","author":"Tezcan","year":"2021","journal-title":"Clin. Rheumatol."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Rol, N., Kurakula, K.B., Happ\u00e9, C., Bogaard, H.J., and Goumans, M.J. (2018). TGF-\u03b2 and BMPR2 Signaling in PAH: Two Black Sheep in One Family. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19092585"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2002341","DOI":"10.1183\/13993003.02341-2020","article-title":"Targeting transforming growth factor-\u03b2 receptors in pulmonary hypertension","volume":"57","author":"Guignabert","year":"2021","journal-title":"Eur. Respir. J."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.drudis.2018.12.001","article-title":"TGF-\u03b2 and BMPRII signalling pathways in the pathogenesis of pulmonary arterial hypertension","volume":"24","author":"Tielemans","year":"2019","journal-title":"Drug Discov. Today"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.tips.2021.04.002","article-title":"Targeting the TGF-\u03b2 signaling pathway for resolution of pulmonary arterial hypertension","volume":"42","author":"Sharmin","year":"2021","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Andre, P., Joshi, S.R., Briscoe, S.D., Alexander, M.J., Li, G., and Kumar, R. (2022). Therapeutic Approaches for Treating Pulmonary Arterial Hypertension by Correcting Imbalanced TGF-\u03b2 Superfamily Signaling. Front. Med., 8.","DOI":"10.3389\/fmed.2021.814222"},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Gore, B., Izikki, M., Mercier, O., Dewachter, L., Fadel, E., Humbert, M., Dartevelle, P., Simonneau, G., Naeije, R., and Lebrin, F. (2014). Key role of the endothelial TGF-\u03b2\/ALK1\/endoglin signaling pathway in humans and rodents pulmonary hypertension. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0100310"},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Kudryashova, T.V., Shen, Y., Pena, A., Cronin, E., Okorie, E., Goncharov, D.A., and Goncharova, E.A. (2018). Inhibitory Antibodies against Activin A and TGF-\u03b2 Reduce Self-Supported, but Not Soluble Factors-Induced Growth of Human Pulmonary Arterial Vascular Smooth Muscle Cells in Pulmonary Arterial Hypertension. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19102957"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.3892\/mmr.2016.4874","article-title":"TGF-\u03b21 inhibits the apoptosis of pulmonary arterial smooth muscle cells and contributes to pulmonary vascular medial thickening via the PI3K\/Akt pathway","volume":"13","author":"Li","year":"2016","journal-title":"Mol. Med. Rep."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1161\/HYPERTENSIONAHA.121.18684","article-title":"Platelet-Derived TGF (Transforming Growth Factor)-\u03b21 Enhances the Aerobic Glycolysis of Pulmonary Arterial Smooth Muscle Cells by PKM2 (Pyruvate Kinase Muscle Isoform 2) Upregulation","volume":"79","author":"Zhu","year":"2022","journal-title":"Hypertension"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1165\/rcmb.2012-0049OC","article-title":"Inhibition of overactive transforming growth factor-\u03b2 signaling by prostacyclin analogs in pulmonary arterial hypertension","volume":"48","author":"Ogo","year":"2013","journal-title":"Am. J. Respir. Cell. Mol. Biol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/d41573-024-00054-y","article-title":"FDA approves Merck & Co\u2019s pulmonary arterial hypertension drug sotatercept","volume":"23","author":"Kingwell","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.jpeds.2020.04.041","article-title":"Elevated Interleukin-6 Levels Predict Clinical Worsening in Pediatric Pulmonary Arterial Hypertension","volume":"223","author":"Chen","year":"2020","journal-title":"J. Pediatr."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1901761","DOI":"10.1183\/13993003.01761-2019","article-title":"Cellular sources of interleukin-6 and associations with clinical phenotypes and outcomes in pulmonary arterial hypertension","volume":"55","author":"Simpson","year":"2020","journal-title":"Eur. Respir. J."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.healun.2022.10.026","article-title":"Circulating markers of inflammation and angiogenesis and clinical outcomes across subtypes of pulmonary arterial hypertension","volume":"42","author":"Hirsch","year":"2023","journal-title":"J. Heart Lung Transplant."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Wang, A.P., Yang, F., Tian, Y., Su, J.H., Gu, Q., Chen, W., Gong, S.X., Ma, X.F., Qin, X.P., and Jiang, Z.S. (2021). Pulmonary Artery Smooth Muscle Cell Senescence Promotes the Proliferation of PASMCs by Paracrine IL-6 in Hypoxia-Induced Pulmonary Hypertension. Front. Physiol., 12.","DOI":"10.3389\/fphys.2021.656139"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"108379","DOI":"10.1016\/j.intimp.2021.108379","article-title":"Protective effects of progesterone on pulmonary artery smooth muscle cells stimulated with Interleukin 6 via blocking the shuttling and transcriptional function of STAT3","volume":"102","author":"Hu","year":"2022","journal-title":"Int. Immunopharmacol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.healun.2017.08.011","article-title":"Interleukin-6 is independently associated with right ventricular function in pulmonary arterial hypertension","volume":"37","author":"Prins","year":"2018","journal-title":"J. Heart Lung Transplant."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1042\/BST20190046","article-title":"Is there a role for prostanoid-mediated inhibition of IL-6 trans-signalling in the management of pulmonary arterial hypertension?","volume":"47","author":"Durham","year":"2019","journal-title":"Biochem. Soc. Trans."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1172\/JCI96462","article-title":"Ectopic upregulation of membrane-bound IL6R drives vascular remodeling in pulmonary arterial hypertension","volume":"128","author":"Tamura","year":"2018","journal-title":"J. Clin. Investig."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.cyto.2015.06.018","article-title":"Enhanced IL-6 trans-signaling in pulmonary arterial hypertension and its potential role in disease-related systemic damage","volume":"76","author":"Jasiewicz","year":"2015","journal-title":"Cytokine"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1146\/annurev.immunol.021908.132612","article-title":"Immunological and inflammatory functions of the interleukin-1 family","volume":"27","author":"Dinarello","year":"2009","journal-title":"Annu. Rev. Immunol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.14336\/AD.2020.0111","article-title":"Pathological Mechanisms and Potential Therapeutic Targets of Pulmonary Arterial Hypertension: A Review","volume":"11","author":"Xiao","year":"2020","journal-title":"Aging Dis."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1177\/2045893217729096","article-title":"Differential IL-1 signaling induced by BMPR2 deficiency drives pulmonary vascular remodeling","volume":"7","author":"Pickworth","year":"2017","journal-title":"Pulm. Circ."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"523684","DOI":"10.1155\/2014\/523684","article-title":"Epigallocatechin gallate attenuates proliferation and oxidative stress in human vascular smooth muscle cells induced by interleukin-1\u03b2 via heme oxygenase-1","volume":"2014","author":"Liu","year":"2014","journal-title":"Mediat. Inflamm."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1161\/ATVBAHA.113.303145","article-title":"Cross talk between vascular smooth muscle cells and monocytes through interleukin-1\u03b2\/interleukin-18 signaling promotes vein graft thickening","volume":"34","author":"Li","year":"2014","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1161\/ATVBAHA.121.317168","article-title":"Caspase-8 Promotes Pulmonary Hypertension by Activating Macrophage-Associated Inflammation and IL-1\u03b2 (Interleukin 1\u03b2) Production","volume":"42","author":"Rong","year":"2022","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1183\/13993003.01448-2015","article-title":"Role of interleukin-1 receptor 1\/MyD88 signalling in the development and progression of pulmonary hypertension","volume":"48","author":"Parpaleix","year":"2016","journal-title":"Eur. Respir. J."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"3","DOI":"10.4049\/jimmunol.1203103","article-title":"MyD88: A critical adaptor protein in innate immunity signal transduction","volume":"190","author":"Warner","year":"2013","journal-title":"J. Immunol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1164\/rccm.201809-1631LE","article-title":"IL-1 Blockade Reduces Inflammation in Pulmonary Arterial Hypertension and Right Ventricular Failure: A Single-Arm, Open-Label, Phase IB\/II Pilot Study","volume":"199","author":"Trankle","year":"2019","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1440-1843.2006.00821.x","article-title":"Increased plasma monocyte chemoattractant protein-1 level in idiopathic pulmonary arterial hypertension","volume":"11","author":"Itoh","year":"2006","journal-title":"Respirology"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1164\/rccm.200610-1559OC","article-title":"Role of endothelium-derived CC chemokine ligand 2 in idiopathic pulmonary arterial hypertension","volume":"176","author":"Sanchez","year":"2007","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"L449","DOI":"10.1152\/ajplung.00004.2015","article-title":"15-Lipoxygenase and 15-hydroxyeicosatetraenoic acid regulate intravascular thrombosis in pulmonary hypertension","volume":"309","author":"Shen","year":"2015","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1007\/s00109-019-01817-6","article-title":"Hypoxia drives cardiac miRNAs and inflammation in the right and left ventricle","volume":"97","author":"Chouvarine","year":"2019","journal-title":"J. Mol. Med."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1142\/S0192415X22500082","article-title":"Effects of Crocin on CCL2\/CCR2 Inflammatory Pathway in Monocrotaline-Induced Pulmonary Arterial Hypertension Rats","volume":"50","author":"Sheng","year":"2022","journal-title":"Am. J. Chin. Med."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/nrcardio.2017.84","article-title":"Epidemiology and treatment of pulmonary arterial hypertension","volume":"14","author":"Lau","year":"2017","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Roger, I., Milara, J., Montero, P., and Cortijo, J. (2021). The Role of JAK\/STAT Molecular Pathway in Vascular Remodeling Associated with Pulmonary Hypertension. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22094980"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1164\/rccm.202006-2169OC","article-title":"Single-Cell Study of Two Rat Models of Pulmonary Arterial Hypertension Reveals Connections to Human Pathobiology and Drug Repositioning","volume":"203","author":"Hong","year":"2021","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1164\/rccm.201707-1370OC","article-title":"Toll-like Receptor 3 Is a Therapeutic Target for Pulmonary Hypertension","volume":"199","author":"Farkas","year":"2019","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.immuni.2012.03.014","article-title":"JAK and STAT signaling molecules in immunoregulation and immune-mediated disease","volume":"36","author":"Plenge","year":"2012","journal-title":"Immunity"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.cellbi.2005.03.014","article-title":"JAK-STAT signaling pathway in pulmonary arterial smooth muscle cells is activated by hypoxia","volume":"29","author":"Wang","year":"2005","journal-title":"Cell Biol. Int."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1136\/thoraxjnl-2017-210728","article-title":"JAK2 mediates lung fibrosis, pulmonary vascular remodelling and hypertension in idiopathic pulmonary fibrosis: An experimental study","volume":"73","author":"Milara","year":"2018","journal-title":"Thorax"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"e12742","DOI":"10.1111\/cpr.12742","article-title":"Blockade of JAK2 protects mice against hypoxia-induced pulmonary arterial hypertension by repressing pulmonary arterial smooth muscle cell proliferation","volume":"53","author":"Zhang","year":"2020","journal-title":"Cell Prolif."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"e244","DOI":"10.3324\/haematol.2014.120816","article-title":"Pulmonary arterial hypertension exacerbated by ruxolitinib","volume":"100","author":"Low","year":"2015","journal-title":"Haematologica"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1038\/leu.2014.5","article-title":"Ruxolitinib leads to improvement of pulmonary hypertension in patients with myelofibrosis","volume":"28","author":"Tabarroki","year":"2014","journal-title":"Leukemia"},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Karpov, A.A., Mihailova, A.M., Shilenko, L.A., Vaulina, D.D., Sidorova, E.E., Akhmetova, A.A., Docshin, P.M., Krasichkov, A.S., Sanarova, K.E., and Moiseeva, O.M. (2022). Inhibition of JAK1,2 Prevents Fibrotic Remodeling of Pulmonary Vascular Bed and Improves Outcomes in the Rat Model of Chronic Thromboembolic Pulmonary Hypertension. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232415646"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1165\/rcmb.2019-0431OC","article-title":"Targeting Jak-Stat Signaling in Experimental Pulmonary Hypertension","volume":"64","author":"Yerabolu","year":"2021","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Fu, M., Luo, F., Wang, E., Jiang, Y., Liu, S., Peng, J., and Liu, B. (2021). Magnolol Attenuates Right Ventricular Hypertrophy and Fibrosis in Hypoxia-Induced Pulmonary Arterial Hypertensive Rats Through Inhibition of the JAK2\/STAT3 Signaling Pathway. Front. Pharmacol., 12.","DOI":"10.3389\/fphar.2021.755077"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1093\/cvr\/cvt105","article-title":"Pathophysiological roles of nuclear factor kappaB (NF-kB) in pulmonary arterial hypertension: Effects of synthetic selective NF-kB inhibitor IMD-0354","volume":"99","author":"Hosokawa","year":"2013","journal-title":"Cardiovasc. Res."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"L934","DOI":"10.1152\/ajplung.00034.2013","article-title":"NF-\u03baB pathway is involved in CRP-induced effects on pulmonary arterial endothelial cells in chronic thromboembolic pulmonary hypertension","volume":"305","author":"Wynants","year":"2013","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1038\/s41401-019-0272-2","article-title":"Crosstalk between the Akt\/mTORC1 and NF-\u03baB signaling pathways promotes hypoxia-induced pulmonary hypertension by increasing DPP4 expression in PASMCs","volume":"40","author":"Li","year":"2019","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.cell.2020.02.041","article-title":"Toll-like Receptors and the Control of Immunity","volume":"180","author":"Fitzgerald","year":"2020","journal-title":"Cell"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.pharmthera.2015.12.005","article-title":"Toll-like receptors mediating vascular malfunction: Lessons from receptor subtypes","volume":"158","author":"Wang","year":"2016","journal-title":"Pharmacol. Ther."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/ni.1863","article-title":"The role of pattern-recognition receptors in innate immunity: Update on Toll-like receptors","volume":"11","author":"Kawai","year":"2010","journal-title":"Nat. Immunol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"11409","DOI":"10.1111\/jcmm.15745","article-title":"Transcriptomic analysis identifies Toll-like and Nod-like pathways and necroptosis in pulmonary arterial hypertension","volume":"24","author":"Xiao","year":"2020","journal-title":"J. Cell. Mol. Med."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1161\/CIRCRESAHA.114.303662","article-title":"Genetic deletion of toll-like receptor 4 on platelets attenuates experimental pulmonary hypertension","volume":"114","author":"Bauer","year":"2014","journal-title":"Circ. Res."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"2300204","DOI":"10.1183\/13993003.00204-2023","article-title":"TLR7\/8 activation induces autoimmune vasculopathy and causes severe pulmonary arterial hypertension","volume":"62","author":"Yeh","year":"2023","journal-title":"Eur. Respir. J."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"e019247","DOI":"10.1161\/JAHA.120.019247","article-title":"Chronic Inhibition of Toll-Like Receptor 9 Ameliorates Pulmonary Hypertension in Rats","volume":"10","author":"Ishikawa","year":"2021","journal-title":"J. Am. Heart Assoc."},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Pullamsetti, S.S., Sitapara, R., Osterhout, R., Weiss, A., Carter, L.L., Zisman, L.S., and Schermuly, R.T. (2023). Pharmacology and Rationale for Seralutinib in the Treatment of Pulmonary Arterial Hypertension. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241612653"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"2002463","DOI":"10.1183\/13993003.02463-2020","article-title":"Mendelian randomisation and experimental medicine approaches to interleukin-6 as a drug target in pulmonary arterial hypertension","volume":"59","author":"Toshner","year":"2022","journal-title":"Eur. Respir. J."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"e12251","DOI":"10.1002\/pul2.12251","article-title":"SATISFY-JP, a phase II multicenter open-label study on Satralizumab, an anti-IL-6 receptor antibody, use for the treatment of pulmonary arterial hypertension in patients with an immune-responsive-phenotype: Study protocol","volume":"13","author":"Tamura","year":"2023","journal-title":"Pulm. Circ."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1172\/JCI120415","article-title":"Classical IL-6 signaling: A promising therapeutic target for pulmonary arterial hypertension","volume":"128","author":"Pullamsetti","year":"2018","journal-title":"J. Clin. Investig."},{"key":"ref_133","doi-asserted-by":"crossref","unstructured":"Cardoneanu, A., Burlui, A.M., Macovei, L.A., Bratoiu, I., Richter, P., and Rezus, E. (2022). Targeting Systemic Sclerosis from Pathogenic Mechanisms to Clinical Manifestations: Why IL-6?. Biomedicines, 10.","DOI":"10.3390\/biomedicines10020318"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1097\/MCP.0000000000001001","article-title":"Scleroderma pulmonary arterial hypertension: The same as idiopathic pulmonary arterial hypertension?","volume":"29","author":"Khan","year":"2023","journal-title":"Curr. Opin. Pulm. Med."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1097\/MCP.0000000000000887","article-title":"Evolving nonvasodilator treatment options for pulmonary arterial hypertension","volume":"28","author":"Medrek","year":"2022","journal-title":"Curr. Opin. Pulm. Med."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1111\/1756-185X.14368","article-title":"Immunosuppressive therapy in patients with connective tissue disease-associated pulmonary arterial hypertension: A systematic review","volume":"25","author":"Ding","year":"2022","journal-title":"Int. J. Rheum. Dis."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"2301107","DOI":"10.1183\/13993003.01107-2023","article-title":"Effects of sotatercept on haemodynamics and right heart function: Analysis of the STELLAR trial","volume":"62","author":"Souza","year":"2023","journal-title":"Eur. Respir. J."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1056\/NEJMoa2024277","article-title":"Sotatercept for the treatment of pulmonary arterial hypertension","volume":"384","author":"Humbert","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"2201347","DOI":"10.1183\/13993003.01347-2022","article-title":"Sotatercept for the treatment of pulmonary arterial hypertension: PULSAR open-label extension","volume":"61","author":"Humbert","year":"2023","journal-title":"Eur. Respir. J."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1056\/NEJMoa2213558","article-title":"Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension","volume":"388","author":"Hoeper","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"2102356","DOI":"10.1183\/13993003.02356-2021","article-title":"Inhaled seralutinib exhibits potent efficacy in models of pulmonary arterial hypertension","volume":"60","author":"Galkin","year":"2022","journal-title":"Eur. Respir. J."},{"key":"ref_142","first-page":"S2213","article-title":"Seralutinib in adults with pulmonary arterial hypertension (TORREY): A randomised, double-blind, placebo-controlled phase 2 trial","volume":"24","author":"Frantz","year":"2024","journal-title":"Lancet Respir. Med."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/15\/8427\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:28:32Z","timestamp":1760110112000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/15\/8427"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,1]]},"references-count":142,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2024,8]]}},"alternative-id":["ijms25158427"],"URL":"https:\/\/doi.org\/10.3390\/ijms25158427","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,1]]}}}